scholarly journals Central retinal vein occlusion: A review of current Evidence-based treatment options

2016 ◽  
Vol 23 (1) ◽  
pp. 44 ◽  
Author(s):  
Stephanie Lu ◽  
Amy Patel ◽  
Christine Nguyen
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Treatment Options ◽  
Current Evidence ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Vein Occlusion ◽  
Central Retinal Vein

scholarly journals Aflibercept Treatment and Regimes in Macular Edema Secondary to Central Retinal Vein Occlusion

2019 ◽  
pp. 29-32
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vision Loss ◽  
Thrombus Formation ◽  
Treatment Options ◽  
Treatment Modalities ◽  
Multiple Treatment ◽  
Vein Occlusion ◽  
Central Retinal Vein

Central retinal vein occlusion (CRVO) is the most common vascular disease leading cause of vision loss after diabetic retinopathy (DR) and branch retinal vein occlusion (BRVO). The pathogenesis of CRVO involves a thrombus formation leading to increased retinal capillary pressure, increased vascular permeability, and possibly retinal neovascularization. Vision loss due to CRVO is commonly caused by macular edema. Multiple treatment modalities have been used to treat macular edema. Currently, the most common therapy modality used is intravitreal inhibition of vascular endothelial growth factor (VEGF). The three most widely used agents are aflibercept, bevacizumab, and ranibizumab. In addition, intraocular steroids can be used to treat macular edema. This review will briefly cover the treatment options and discuss in greater detail the efficacy and safety of aflibercept.

Intravitreal Bevacizumab Injection and Treatment Regimens in Macular Edema Due to Central Retinal Vein Occlusion

2019 ◽  
pp. 33-37
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vision Loss ◽  
Treatment Options ◽  
Intravitreal Bevacizumab ◽  
Treatment Modalities ◽  
Vegf Inhibitors ◽  
Vein Occlusion ◽  
Central Retinal Vein

Central retinal vein occlusion (CRVO) is the second most common vascular disease leading cause of vision loss together with branch retinal vein occlusion (BRVO) after diabetic retinopathy (DR). Vision loss due to CRVO is commonly caused by macular edema and multiple treatment modalities have been used to treat macular edema. In clinical practice, VEGF inhibitors are now the first-line treatment offered to patients who have CRVO with macular edema. The two agents approved by the FDA for the treatment of macular edema are aflibercept and ranibizumab. Bevacizumab is another VEGF inhibitor that has been used off-label to treat macular edema. Several studies have demonstrated that bevacizumab is effective in improving vision and decreasing central macular thickness when used in patients with macular edema due to central retinal vein occlusions. In the current review, the treatment options will be evaluated briefly and the efficacy and safety of bevacizumab will be discussed in greater detail.

Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review

Ophthalmology ◽  
2010 ◽  
Vol 117 (6) ◽  
pp. 1113-1123.e15 ◽  
Author(s):  
Rachel L. McIntosh ◽  
Sophie L. Rogers ◽  
Lyndell Lim ◽  
Ning Cheung ◽  
Jie Jin Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Natural History ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Evidence Based ◽  
Vein Occlusion ◽  
History Of ◽  
Central Retinal Vein

scholarly journals Surgical Treatment in Central Retinal Vein Occlusion

2019 ◽  
pp. 58-63
Keyword(s):  
Surgical Treatment ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Treatment Modalities ◽  
Surgical Approaches ◽  
Vein Occlusion ◽  
Systemic Treatments ◽  
Central Retinal Vein

Retinal vein occlusion (RVO) is the second most common vascular disease after diabetic retinopathy. Central retinal vein occlusion (CRVO) is less common than branched retinal vein occlusion. There are different aspects of the mechanisms underlying etiology and optimal treatment strategies in CRVO. There are various treatment modalities for CRVO including observation, systemic treatments, intravitreal agents, laser photocoagulation, fibrinolytic treatment, and surgical approaches. Despite most of the treatment strategies are directed at secondary complications of CRVO that affect vision including macular edema and retinal neovascularization, some treatment options also have the ability to create a bypass around the obstructed retinal vein and to decrease the raised venous hydrostatic pressure. The aim of this review is to describe the outcomes of surgical treatment modalities for CRVO.

Hypercoagulability and High Lipoprotein(a) Levels in Patients with Central Retinal Vein Occlusion

1994 ◽  
Vol 72 (01) ◽  
pp. 039-043 ◽  
Author(s):  
Francesco Bandello ◽  
Silvana Vigano’ D’Angelo ◽  
Mariella Parlavecchia ◽  
Alessandra Tavola ◽  
Patrizia Della Valle ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Specific Treatment ◽  
Fibrin Deposition ◽  
Heparin Cofactor Ii ◽  
Lipoprotein A ◽  
Vein Occlusion ◽  
Acute Event ◽  
D Dimer ◽  
Central Retinal Vein

SummaryA series of coagulation parameters and lipoprotein(a) (Lp(a)) were explored in plasma from 40 patients with central retinal vein occlusion (CRVO, non-ischemic type n = 12; ischemic type n = 28) free of local and systemic predisposing factors, 1 to 12 months after the acute event. Forty age- and sex-matched patients with cataract served as controls. Prothrombin fragment 1.2 (FI.2), D-dimer, FVII:C - but not FVII: Ag - were higher and fibrinogen was lower in CRVO patients than in controls. Patients with non-ischemic CRVO had higher FI .2 and FVII:C and lower heparin cofactor II than patients with ischemic CRVO. Lp(a) levels greater than 300 mg/1 were observed in 12 patients with CRVO and in 4 controls (30% vs 10%, p <0.025). Patients with high Lp(a) - consistently associated with the S2 phenotype - had higher FVII:C, FVII:C/Ag ratio, and fibrinogen than the remaining CRVO patients. Plasma FI.2 and D-dimer correlated fairly in controls (r = 0.41) and patients with normal Lp(a) levels (r = 0.55), but they did not in the group of patients with high Lp(a) (r = 0.19), where the latter parameter was negatively related to D-dimer (r = −0.55). There was no dependence of the abnormalities observed on the time elapsed from vein occlusion. The findings of activated FVII and high FI.2, D-dimer, and Lp(a) are not uncommon in patients with CRVO. Increased thrombin formation with fibrin deposition and impaired fibrinolysis may play a role in the pathophysiology of CRVO and require specific treatment

Retinal Vascular Occlusive Disorders - Risk Factors

2018 ◽  
Vol 3 (02) ◽  
Author(s):  
Shivcharan Lal Chandravanshi, Sunil Kumar Shrivastava, Priyanka Agnihotri, Smriti Gupta
Keyword(s):  
Risk Factors ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Retinal Artery Occlusion ◽  
Artery Occlusion ◽  
Vein Occlusion ◽  
Department Of Ophthalmology ◽  
Retinal Artery ◽  
Central Retinal Vein

Aims and Objective - The aim of the present study is to identify risk factors associated with different retinal vascular occlusive diseases (RVOD), such as central retinal artery occlusion (CRAO), hemi-retinal artery occlusion (HRAO), branch retinal artery occlusion (BRAO), cilioretinal artery occlusion (Cilio-RAO), central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), and hemi-retinal vein occlusion (HRVO). Patients and Method - A cross-sectional study on 114 consecutive subjects, aged 24-96 years who have attended at the outpatient department of ophthalmology at Shyam Shah Medical College, Rewa, MP, were included in the study. The Duration of study was January 2016 to December 2017. Only patients with CRAO, BRAO, HRAO, Cilio-RAO, CRVO, BRVO, and HRVO were included in the study. Other retinal vascular disorders such as diabetic vaso-occlusive disease, anterior and posterior ischemic and non-ischemic neuropathy, hypertensive retinopathy, sickle cell retinopathy, retinal telangiectasia, retinopathy of prematurity, were excluded from study. Results - We have included 114 patients, 64 cases (56.14%) males, 50 (43.85%) females, aged 56+/-8 years (range 24-96 years).  Bilateral retinal vascular occlusive disorders were seen in only 4 cases (3.5%). Two patients have bilateral CRVO followed by one case of bilateral BRVO and one case of bilateral CRAO.  Out of 114 patients, branch retinal vein occlusion was seen in 62 cases (54.38%), followed by central retinal vein occlusion in 36 cases (31.57%), CRAO in 8 cases (7.01%), and hemi- retinal vein occlusion in 4 cases (3.50%). Hypertension was the most common, (40 cases, 35.08%) risk factor identified for retinal vascular occlusive disorders followed by diabetes 24 cases (21.05%), combined diabetes and hypertension in 22 cases (19.29%), and atherosclerosis in 18 cases (15.78%). Conclusions - Retinal vascular occlusive diseases have systemic as well as ocular risk factors. Understanding of these risk factors is essential for proper treatment of RVOD. Timely identification of risk factors for RVOD may helpful in decreasing ocular and systemic morbidity in these patients.

Sign in / Sign up

Export Citation Format

Share Document